근이완제 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

The future of the global muscle relaxant drug market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The global muscle relaxant drug market is expected to reach an estimated $14 billion by 2035 with a CAGR of 6.1% from 2026 to 2035. The major drivers for this market are the increasing demand for prevalence of musculoskeletal disorders, the rising adoption in hospital & clinic settings, and the growing demand for non-invasive pain management.

• Lucintel forecasts that, within the type category, centrally acting muscle relaxant is expected to witness higher growth over the forecast period.
• Within the application category, hospital pharmacy is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Muscle Relaxant Drug Market

The muscle relaxant drug market is experiencing rapid evolution driven by technological advancements, changing healthcare needs, and increasing awareness of musculoskeletal conditions. As populations age and the prevalence of chronic pain and spasticity rises, the demand for effective muscle relaxants is growing. Innovations in drug formulation, personalized medicine, and regulatory support are shaping the future landscape. Additionally, the integration of digital health tools and a focus on safer, more targeted therapies are influencing market dynamics. These developments are not only expanding market opportunities but also improving patient outcomes, making the industry more competitive and innovative.

• Technological Advancements: The development of new drug delivery systems and formulations enhances efficacy and patient compliance. Innovations such as transdermal patches, injectables, and sustained-release formulations allow for better targeting and reduced side effects. These advancements improve therapeutic outcomes and expand options for clinicians, fostering market growth. The integration of nanotechnology and biotechnology further enables precision medicine approaches, making treatments more personalized and effective. As technology continues to evolve, the market is poised for increased innovation, leading to more effective and safer muscle relaxant therapies.
• Rising Prevalence of Musculoskeletal Disorders: An ageing population and sedentary lifestyles contribute to a surge in conditions like spasticity, back pain, and muscle spasms. This increased prevalence drives demand for muscle relaxants across healthcare settings. Governments and healthcare providers are prioritizing musculoskeletal health, leading to increased screening and diagnosis. Consequently, pharmaceutical companies are investing in developing new and improved muscle relaxants to meet this growing need. The market is expanding as more patients seek relief from chronic pain and mobility issues, emphasizing the importance of accessible and effective treatments.
• Focus on Safety and Side Effect Reduction: Safety concerns related to traditional muscle relaxants, such as sedation and dependency, are prompting the industry to develop safer alternatives. Regulatory agencies are encouraging the development of drugs with fewer adverse effects. This trend is leading to the introduction of novel compounds and formulations that minimize risks. Enhanced safety profiles improve patient adherence and expand the use of muscle relaxants in vulnerable populations, including the elderly and those with comorbidities. The focus on safety is reshaping product development priorities and influencing market competition.
• Personalized Medicine and Targeted Therapies: Advances in genomics and biomarker research enable the customization of muscle relaxant treatments. Personalized approaches improve efficacy and reduce adverse effects by tailoring therapies to individual patient profiles. This trend is fostering the development of targeted drugs that address specific genetic or molecular markers associated with musculoskeletal conditions. The shift toward personalized medicine is creating new market segments and opportunities for innovative therapies, ultimately leading to more effective and patient-centric care.
• Digital Health Integration and Telemedicine: The adoption of digital tools and telehealth services is transforming how muscle relaxant treatments are managed. Remote monitoring, virtual consultations, and mobile health apps facilitate better patient engagement and adherence. Digital platforms also enable real-time tracking of treatment outcomes, allowing for more precise adjustments. This integration enhances access to care, especially in remote or underserved areas, and supports personalized treatment plans. The market is increasingly incorporating digital health solutions, which improve treatment efficiency and patient satisfaction, and open new avenues for market expansion.

These emerging trends are collectively reshaping the muscle relaxant drug market by fostering innovation, improving safety, and expanding access. They are driving the development of more effective, personalized, and patient-friendly therapies, ultimately enhancing treatment outcomes and market competitiveness. As these trends continue to evolve, the industry is set to experience sustained growth and transformation.

Recent Developments in the Muscle Relaxant Drug Market

The muscle relaxant drug market is experiencing rapid growth driven by increasing prevalence of musculoskeletal disorders, advancements in pharmaceutical research, and rising awareness of treatment options. Technological innovations and expanding healthcare infrastructure are also contributing to market expansion. These developments are creating new opportunities for manufacturers and healthcare providers, ultimately improving patient outcomes. As the market evolves, stakeholders are focusing on innovation, accessibility, and personalized treatments to meet growing demand and address unmet medical needs.

• Growing Prevalence of Musculoskeletal Disorders: The rising incidence of conditions like back pain, spasticity, and fibromyalgia is fueling demand for effective muscle relaxants, expanding market size and encouraging pharmaceutical companies to develop targeted therapies.
• Advances in Drug Formulation and Delivery: Innovations such as extended-release formulations and transdermal patches improve patient compliance and treatment efficacy, leading to increased adoption of muscle relaxants and opening new avenues for product development.
• Increasing Focus on Personalized Medicine: Tailoring muscle relaxant treatments based on genetic and clinical profiles enhances effectiveness and reduces side effects, driving market growth and encouraging research into customized therapies.
• Expansion of healthcare infrastructure in emerging markets: Improved healthcare access and infrastructure in developing regions are facilitating wider distribution and use of muscle relaxants, significantly boosting market penetration and revenue streams.
• Rising awareness and adoption of minimally invasive therapies: Education campaigns and technological advancements promote less invasive treatment options, increasing patient acceptance and expanding the market for muscle relaxants as part of comprehensive care.

The overall impact of these developments is a robust expansion of the muscle relaxant drug market, driven by innovation, increased accessibility, and personalized treatment approaches. This growth benefits manufacturers, healthcare providers, and patients by offering more effective, targeted, and accessible therapies, ultimately improving health outcomes and market competitiveness.

Strategic Growth Opportunities in the Muscle Relaxant Drug Market

The muscle relaxant drug market is experiencing significant growth driven by the increasing prevalence of musculoskeletal disorders, neurological conditions, and the demand for effective pain management solutions. Advances in pharmaceutical research, rising geriatric populations, and expanding healthcare infrastructure further contribute to market expansion. Strategic collaborations and technological innovations are also opening new avenues for growth. Understanding these opportunities helps stakeholders capitalize on emerging trends and enhance their market positioning in this competitive landscape.

• Expanding use in Neurological Disorder Treatments: Muscle relaxants are increasingly used to treat neurological conditions such as multiple sclerosis, cerebral palsy, and stroke-related spasticity. Growing awareness and improved diagnostic techniques are driving demand for these drugs. Additionally, ongoing research into new formulations and delivery methods enhances their efficacy and safety profiles, broadening their application scope. This expansion offers significant growth potential for pharmaceutical companies focusing on neurological therapeutics.
• Rising demand for Minimally Invasive Pain Management Options: As patients seek less invasive treatments, muscle relaxants are becoming preferred options for managing acute and chronic musculoskeletal pain. Their ability to reduce muscle spasms and improve mobility makes them attractive alternatives to surgical interventions. The development of targeted, fast-acting formulations and combination therapies further boosts their appeal. This trend is expected to increase market penetration, especially in outpatient and primary care settings.
• Increasing Adoption in Sports Medicine and Physical Therapy: Muscle relaxants are increasingly used in sports medicine to treat muscle strains, sprains, and overuse injuries. Physical therapists and sports physicians favor these drugs for their quick relief and ability to facilitate rehabilitation. The rising popularity of sports activities and awareness of injury management are fueling demand. Innovations in drug delivery and formulations tailored for athletic use are likely to expand market opportunities in this segment.
• Growing Focus on Personalized Medicine and Targeted Therapies: Advances in pharmacogenomics and biomarker research are enabling more personalized treatment approaches with muscle relaxants. Tailoring therapies based on individual genetic profiles improves efficacy and reduces adverse effects. This shift toward precision medicine encourages the development of specialized formulations and dosing regimens, opening new avenues for market growth. Companies investing in research and development of targeted muscle relaxant therapies are poised to benefit from this trend.
• Strategic Collaborations and Technological Innovations Driving Market Expansion: Partnerships between pharmaceutical firms, biotech companies, and research institutions are accelerating the development of novel muscle relaxants. Innovations such as sustained-release formulations, injectable gels, and combination therapies enhance treatment options. These collaborations facilitate regulatory approvals and market entry, boosting overall growth. Additionally, advancements in drug delivery technologies improve patient compliance and outcomes, further propelling market expansion across diverse applications.

These growth opportunities collectively are set to significantly influence the muscle relaxant drug market, fostering innovation, expanding applications, and increasing accessibility. Stakeholders who leverage these trends can enhance their competitive edge and capitalize on the expanding demand for effective muscle relaxation therapies worldwide.

Muscle Relaxant Drug Market Driver and Challenges

The muscle relaxant drug market is influenced by a variety of technological, economic, and regulatory factors that shape its growth and development. Advances in pharmaceutical technology have led to more effective and targeted treatments, while economic conditions impact affordability and accessibility. Regulatory policies govern drug approval processes and safety standards, affecting market entry and innovation. Additionally, the increasing prevalence of musculoskeletal disorders and neurological conditions drives demand, but challenges such as regulatory hurdles, side effect concerns, and market competition also pose significant obstacles. Understanding these drivers and challenges is essential for stakeholders aiming to navigate and capitalize on this evolving market landscape.

The factors responsible for driving the muscle relaxant drug market include:-

• Technological Advancements: The development of new formulations and delivery methods, such as injectable and oral options, enhances treatment efficacy and patient compliance. Innovations like botulinum toxin therapies have expanded indications, improving outcomes for conditions like spasticity and dystonia. These technological improvements attract investment, foster research, and accelerate market growth by offering safer, more effective options.
• Rising Prevalence of Musculoskeletal and Neurological Disorders: Increasing incidences of conditions such as back pain, cerebral palsy, and multiple sclerosis are fueling demand for muscle relaxants. Ageing populations and sedentary lifestyles contribute to higher case numbers, prompting healthcare providers to seek effective management options. This growing patient base directly boosts market sales and encourages pharmaceutical companies to expand their product portfolios.
• Regulatory Approvals and Support: Stringent regulatory frameworks ensure drug safety and efficacy, fostering consumer confidence. Approval of new muscle relaxants and expanded indications for existing drugs facilitate market expansion. Supportive policies and fast-track approval processes in certain regions accelerate product launches, enabling companies to capitalize on unmet medical needs and increase market share.
• Increasing Healthcare Expenditure: Rising healthcare budgets and insurance coverage improve access to advanced treatments, including muscle relaxants. As healthcare systems prioritize effective management of chronic conditions, demand for these drugs rises. This economic support encourages pharmaceutical companies to invest in research and marketing, further propelling market growth.
• Growing Awareness and Diagnosis: Enhanced awareness campaigns and improved diagnostic techniques lead to earlier detection of musculoskeletal and neurological conditions. Early diagnosis results in timely treatment with muscle relaxants, increasing their utilization. This trend supports sustained market growth by expanding the patient population eligible for these therapies.

The challenges facing the market include:-

• Regulatory Hurdles and Approval Delays: Navigating complex regulatory landscapes can delay product launches and increase costs. Stringent safety and efficacy requirements necessitate extensive clinical trials, which prolong time-to-market. These hurdles can hinder innovation and reduce competitiveness, especially for smaller firms lacking resources to meet regulatory demands.
• Side Effects and Safety Concerns: Muscle relaxants are associated with adverse effects such as drowsiness, dependency, and muscle weakness, which can limit their use. Safety concerns lead to cautious prescribing practices and restrict market penetration, especially in vulnerable populations like children and the elderly. Managing these risks is crucial for maintaining market growth and patient trust.
• Market Competition and Patent Expirations: The presence of multiple players and generic versions intensifies competition, leading to price reductions and reduced profit margins. Patent expirations for key drugs open the market to generics, impacting revenue streams for original manufacturers. Companies must innovate continuously to maintain a competitive edge amid increasing market saturation.

the muscle relaxant drug market is driven by technological innovations, rising disease prevalence, regulatory support, economic factors, and increased awareness. However, regulatory challenges, safety concerns, and intense competition pose significant hurdles. These dynamics collectively influence market growth, requiring stakeholders to adapt strategies that leverage opportunities while mitigating risks. Overall, the market's future will depend on balancing innovation with safety and navigating regulatory complexities to meet the growing demand for effective muscle relaxation therapies.

List of Muscle Relaxant Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies muscle relaxant drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the muscle relaxant drug companies profiled in this report include-

• Amneal Pharmaceuticals LLC
• lpsen Biopharmaceuticals, Inc.
• Merz Pharmaceuticals, LLC.
• Par Pharmaceutical
• Endo Pharmaceuticals
• Vertical Pharmaceuticals
• Mallinckrodt
• SteriMax
• Eisai
• Metacel Pharmaceuticals, LLC.

Muscle Relaxant Drug Market by Segment

The study includes a forecast for the global muscle relaxant drug market by type, drug class, route of administration, application, and region.

Muscle Relaxant Drug Market by Type [Value from 2019 to 2035]:

• Centrally Acting Muscle Relaxants
• Peripherally Acting Muscle Relaxants

Muscle Relaxant Drug Market by Drug Class [Value from 2019 to 2035]:

• Benzodiazepine Derivative
• Non-Benzodiazepine Relaxant
• Depolarizing Blocker
• Non-Depolarizing Blocker

Muscle Relaxant Drug Market by Route of Administration [Value from 2019 to 2035]:

• Oral
• Intravenous Injection
• Intramuscular Injection

Muscle Relaxant Drug Market by Application [Value from 2019 to 2035]:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Muscle Relaxant Drug Market by Region [Value from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Muscle Relaxant Drug Market

The muscle relaxant drug market has experienced significant shifts driven by technological advancements, regulatory changes, and evolving healthcare needs across the globe. Countries are focusing on developing innovative formulations, expanding access, and addressing unmet medical needs. The United States, China, Germany, India, and Japan are key players, each contributing uniquely to the market's growth through research, policy reforms, and increasing demand for effective treatments. These developments reflect a broader trend towards personalized medicine and improved patient outcomes, shaping the future landscape of muscle relaxant therapies worldwide.

• United States: The US market has seen increased investment in research and development, leading to the approval of new muscle relaxants with improved efficacy and fewer side effects. Regulatory agencies like the FDA are streamlining approval processes, encouraging innovation. There is also a rising demand for combination therapies and targeted treatments, driven by an ageing population and rising prevalence of musculoskeletal disorders. Telemedicine adoption has facilitated better patient access and management of muscle relaxant therapies.
• China: China is experiencing rapid growth in the muscle relaxant market due to expanding healthcare infrastructure and increasing awareness of musculoskeletal conditions. Local pharmaceutical companies are investing in developing generic and branded drugs, with some gaining approval for domestic use. Government initiatives to improve healthcare access and affordability are boosting market penetration. Additionally, traditional Chinese medicine is being integrated with modern therapies, offering alternative treatment options.
• Germany: Germany's market is characterized by high-quality standards and a focus on innovative drug formulations. The country is a leader in clinical research and has a strong regulatory framework that promotes safety and efficacy. There is a growing trend towards personalized medicine, with new muscle relaxants tailored to specific patient needs. The ageing population and rising incidence of chronic pain conditions are driving demand for advanced therapies. Germany also emphasizes sustainable manufacturing practices and digital health integration.
• India: India's muscle relaxant market is rapidly expanding, fueled by increasing prevalence of musculoskeletal disorders and a large, ageing population. The country's pharmaceutical industry is focusing on cost-effective generics and biosimilars to meet domestic demand. Government initiatives to improve healthcare infrastructure and insurance coverage are facilitating wider access. There is also a rising trend of local manufacturing and research collaborations to develop innovative therapies suited to regional needs.
• Japan: Japan's market is characterized by high healthcare standards and a focus on ageing-related conditions. The country is investing in research to develop novel muscle relaxants with improved safety profiles. Technological advancements, such as digital health tools, are being integrated into treatment plans. The ageing population is driving demand for long-term management options for chronic musculoskeletal conditions. Japan also emphasizes regulatory rigor and sustainable practices, fostering innovation within a highly developed healthcare system.

Features of the Global Muscle Relaxant Drug Market

• Market Size Estimates: Muscle relaxant drug market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2025) and forecast (2026 to 2035) by various segments and regions.
• Segmentation Analysis: Muscle relaxant drug market size by various segments, such as by type, drug class, route of administration, application, and region in terms of value ($B).
• Regional Analysis: Muscle relaxant drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, drug class, route of administration, applications, and regions for the muscle relaxant drug market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the muscle relaxant drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the muscle relaxant drug market by type (centrally acting muscle relaxants and peripherally acting muscle relaxants), drug class (benzodiazepine derivative, non-benzodiazepine relaxant, depolarizing blocker, and non-depolarizing blocker), route of administration (oral, intravenous injection, and intramuscular injection), application (hospital pharmacy, retail pharmacy, and online pharmacy), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 7 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Muscle Relaxant Drug Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Centrally Acting Muscle Relaxants : Trends and Forecast (2019-2035)
• 4.4 Peripherally Acting Muscle Relaxants : Trends and Forecast (2019-2035)

5. Global Muscle Relaxant Drug Market by Drug Class

• 5.1 Overview
• 5.2 Attractiveness Analysis by Drug Class
• 5.3 Benzodiazepine Derivative : Trends and Forecast (2019-2035)
• 5.4 Non-Benzodiazepine Relaxant : Trends and Forecast (2019-2035)
• 5.5 Depolarizing Blocker : Trends and Forecast (2019-2035)
• 5.6 Non-Depolarizing Blocker : Trends and Forecast (2019-2035)

6. Global Muscle Relaxant Drug Market by Route of Administration

• 6.1 Overview
• 6.2 Attractiveness Analysis by Route of Administration
• 6.3 Oral : Trends and Forecast (2019-2035)
• 6.4 Intravenous Injection : Trends and Forecast (2019-2035)
• 6.5 Intramuscular Injection : Trends and Forecast (2019-2035)

7. Global Muscle Relaxant Drug Market by Application

• 7.1 Overview
• 7.2 Attractiveness Analysis by Application
• 7.3 Hospital Pharmacy : Trends and Forecast (2019-2035)
• 7.4 Retail Pharmacy : Trends and Forecast (2019-2035)
• 7.5 Online Pharmacy : Trends and Forecast (2019-2035)

8. Regional Analysis

• 8.1 Overview
• 8.2 Global Muscle Relaxant Drug Market by Region

9. North American Muscle Relaxant Drug Market

• 9.1 Overview
• 9.2 North American Muscle Relaxant Drug Market by Type
• 9.3 North American Muscle Relaxant Drug Market by Application
• 9.4 The United States Muscle Relaxant Drug Market
• 9.5 Canadian Muscle Relaxant Drug Market
• 9.6 Mexican Muscle Relaxant Drug Market

10. European Muscle Relaxant Drug Market

• 10.1 Overview
• 10.2 European Muscle Relaxant Drug Market by Type
• 10.3 European Muscle Relaxant Drug Market by Application
• 10.4 German Muscle Relaxant Drug Market
• 10.5 French Muscle Relaxant Drug Market
• 10.6 Italian Muscle Relaxant Drug Market
• 10.7 Spanish Muscle Relaxant Drug Market
• 10.8 The United Kingdom Muscle Relaxant Drug Market

11. APAC Muscle Relaxant Drug Market

• 11.1 Overview
• 11.2 APAC Muscle Relaxant Drug Market by Type
• 11.3 APAC Muscle Relaxant Drug Market by Application
• 11.4 Chinese Muscle Relaxant Drug Market
• 11.5 Indian Muscle Relaxant Drug Market
• 11.6 Japanese Muscle Relaxant Drug Market
• 11.7 South Korean Muscle Relaxant Drug Market
• 11.8 Indonesian Muscle Relaxant Drug Market

12. ROW Muscle Relaxant Drug Market

• 12.1 Overview
• 12.2 ROW Muscle Relaxant Drug Market by Type
• 12.3 ROW Muscle Relaxant Drug Market by Application
• 12.4 Middle Eastern Muscle Relaxant Drug Market
• 12.5 South American Muscle Relaxant Drug Market
• 12.6 African Muscle Relaxant Drug Market

13. Competitor Analysis

• 13.1 Product Portfolio Analysis
• 13.2 Operational Integration
• 13.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 13.4 Market Share Analysis

14. Opportunities & Strategic Analysis

• 14.1 Value Chain Analysis
• 14.2 Growth Opportunity Analysis
  • 14.2.1 Growth Opportunity by Type
  • 14.2.2 Growth Opportunity by Drug Class
  • 14.2.3 Growth Opportunity by Route of Administration
  • 14.2.4 Growth Opportunity by Application
• 14.3 Emerging Trends in the Global Muscle Relaxant Drug Market
• 14.4 Strategic Analysis
  • 14.4.1 New Product Development
  • 14.4.2 Certification and Licensing
  • 14.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

15. Company Profiles of the Leading Players Across the Value Chain

• 15.1 Competitive Analysis Overview
• 15.2 Amneal Pharmaceuticals LLC
  • Company Overview
  • Muscle Relaxant Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.3 lpsen Biopharmaceuticals, Inc.
  • Company Overview
  • Muscle Relaxant Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.4 Merz Pharmaceuticals, LLC.
  • Company Overview
  • Muscle Relaxant Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.5 Par Pharmaceutical
  • Company Overview
  • Muscle Relaxant Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.6 Endo Pharmaceuticals
  • Company Overview
  • Muscle Relaxant Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.7 Vertical Pharmaceuticals
  • Company Overview
  • Muscle Relaxant Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.8 Mallinckrodt
  • Company Overview
  • Muscle Relaxant Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.9 SteriMax
  • Company Overview
  • Muscle Relaxant Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.10 Eisai
  • Company Overview
  • Muscle Relaxant Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.11 Metacel Pharmaceuticals, LLC.
  • Company Overview
  • Muscle Relaxant Drug Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

16. Appendix

• 16.1 List of Figures
• 16.2 List of Tables
• 16.3 Research Methodology
• 16.4 Disclaimer
• 16.5 Copyright
• 16.6 Abbreviations and Technical Units
• 16.7 About Us
• 16.8 Contact Us